In addition, an independent cohort of patients further validated the association between high FGF12 gene expression and shortened overall survival (OS) in uterine sarcoma patients (Supplementary Figure S3C), suggesting that FGF12 could potentially be a prognostic biomarker for ESS. Here, FGF12 is linked to uterine corpus sarcoma.